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Abstract: A previous preliminary investigation based on a novel MRI approach to map anatomical con-
nectivity revealed areas of increased connectivity in Alzheimer’s disease (AD) but not in mild cognitive
impairment patients. This prompted the hypothesis tested here, that these areas might reflect phenomena
of brain plasticity driven by acetylcholinesterase inhibitors (AChEIs). Thirty-eight patients with probable
AD (19 under medication with AChEIs and 19 drug-naı̈ve) were recruited together with 11 healthy con-
trols. All subjects had MRI scanning at 3T, including volumetric and diffusion-weighted scans. Probabilis-
tic tractography was used to initiate streamlines from all parenchymal voxels, and anatomical
connectivity maps (ACMs) were obtained by counting, among the total number of streamlines initiated,
the fraction passing through each brain voxel. After normalization into standard space, ACMs were used
to test for between-group comparisons, and for interactions between the exposure to AChEIs and global
level of cognition. Patients with AD had reduced ACM values in the fornix, cingulum, and supramarginal
gyri. The ACM value was strongly associated with the AChEI dosage-x-duration product in the anterior
limb (non-motor pathway) of the internal capsule. Tractography from this region identified the anterior
thalamic radiation as the main white matter (WM) tract passing through it. The reduced connectivity in
WM bundles connecting the hippocampi with the rest of the brain (fornix/cingulum) suggests a possible
mechanism for the spread of AD pathology. An intriguing explanation for the interaction between
AChEIs and ACM is related to the mechanisms of brain plasticity, partially driven by neurotrophic prop-
erties of acetylcholine replacement. Hum Brain Mapp 34:3158–3167, 2013. VC 2012 Wiley Periodicals, Inc.




It is becoming increasingly clearer that the clinical mani-
festations of Alzheimer’s disease (AD) are not only associ-
ated with regional gray matter (GM) loss [Bozzali et al.,
2008; Frisoni et al., 2007; Karas et al., 2003; Raji et al., 2009;
Serra et al., 2010a], but also with abnormal integration
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between cortical regions by disconnection mechanisms
[Bozzali et al., 2011a; Gili et al., 2011; Villain et al., 2005].
This concept is supported by both associations found
between measures of white matter (WM) integrity and
measures of cognitive disability in AD [Bozzali et al., 2002;
Bozzali et al., 2011a; Serra et al., 2010a], and by functional
imaging data [Ibáñez et al., 1998; Nestor et al., 2003]. It
has been recently shown that disconnection may precede
the occurrence of GM loss in certain regions of AD brains,
suggesting that GM atrophy is partially due to neuronal
deafferentation [Gili et al., 2011]. We recently employed a
novel approach based on diffusion MRI and tractography,
namely anatomical connectivity mapping (ACM), to obtain
a scalar measure of structural brain connectivity [Bozzali
et al., 2011b]. An exploratory investigation in patients with
AD and mild cognitive impairment (MCI) revealed, as
expected, some brain areas of decreased anatomical con-
nectivity at different clinical stages. Additionally, unex-
pected regions of increased connectivity were also
observed in AD but not in MCI patients. There are many
possible reasons that may account for this difference in
ACM between AD and MCI patients. MCI is known to
represent quite a heterogeneous population, which
includes individuals at a ‘‘prodromal’’ AD stage, individu-
als who will convert to non-AD forms of dementia, and
individuals who will remain stable or will even revert
back to normality [Perri et al., 2007, 2009; Petersen, 2004].
Our MCI patients were all of amnestic type and, according
to the inclusion criteria, they had not to show any remark-
able sign of vascular pathology [Bozzali et al., 2011b].
They have been clinically followed-up (at 6 months inter-
vals) for 2 years after recruitment, revealing a higher an-
nual rate of conversion to AD (50%) than expected from
previous literature [Petersen, 2004]. This suggests that our
cohort of MCI patients was in large part belonging to the
stage of ‘‘prodromal’’ AD. In this perspective, the two
major discriminating factors between our AD and MCI
patients were: (1) the disease duration and (2) the adminis-
tration of acetylcholinestarase inhibitors (AChEIs) to the
patients with AD only. With respect to the latter discrimi-
nating factor, there is increasing evidence that replacement
of acetylcholine levels (by inhibition of cholinesterase
enzymes) produces neurobiological effects, such as modu-
lation of the b-amyloid cascade, neuroprotection, anti-
inflammation, and also promyelination, which exceed
those strictly related with improvement of cognitive effi-
ciency. Despite the difficulty of translating basic research
findings into therapeutic effects in humans, AChEIs have
been demonstrated to reduce, by muscarinic stimulation
(M1 and M3 receptors), unbalances in the metabolism of
the APP (i.e., Amyloid Precursor Protein), thus impacting
on the deposition of Ab proteins [Svensson and Giacobini,
2000]. Protection against glutamate neurotoxicity has been
also attributed to AChEIs, as an effect due to stimulation
of a4- and a7 nicotinic receptors [Pepeu and Giovanni,
2010]. As mentioned earlier, it has also been proposed that
part of AChEIs efficacy may be due to non-synaptic
effects, such as anti-inflammation and promyelination.
With respect to anti-inflammation, it has been proposed
that AChEIs may affect astrocytes and microglia in the
same way as they affect T cells, by harnessing the anti-
inflammatory effect of a7 nicotinic receptors [Reale et al.,
2004, 2006]. With respect to promyelination, which is par-
ticularly interesting for the current study, cholinergic stim-
ulation of oligodendrocytes has been demonstrated to
promote myelination during development, and myelin
repair in older age [Bartzokis et al., 2007].
Against this background, the increased ACM we previ-
ously observed in patients with AD only [Bozzali et al.,
2011b] can be interpreted as a consequence of the occur-
rence of phenomena of brain plasticity, which might be ei-
ther spontaneous or driven by AChEIs. To address this
issue, we planned the current study with the following
specific aims: (i) to confirm the patterns of altered struc-
tural connectivity in a larger population of patients with
AD and (ii) to assess, by correlation analysis, the effect of




Thirty-eight patients diagnosed with probable AD by
NINCDS-ADRDA consensus criteria [McKhann et al.,
1984] were recruited. Nineteen patients were under medi-
cation with AChEIs (8 Rivastigmine and 11 Donepezil),
whereas 19 were drug-naı̈ve. Thirteen out of these 19
patients (68.4%) were enrolled in the study at their first
clinical assessment (and for this reason were drug-naı̈ve).
The remaining six patients (31.6%) had clinical conditions
which prevented the administration of AChEIs (cardiac
ischemia, or history of peptic ulcer). Patients being treated
with AChEIs had to be under therapy for an interval
between 6 months and 2 years at the time of enrollment.
The AChEIs dosage could range between 5 and 10 mg
daily of Donepezil or 6 and 12 mg daily of Rivastigmine.
As shown in Table I, there was no significant difference
between the two subgroups of patients (those under medi-
cation and those drug-naı̈ve) with respect to mean age,
disease duration (calculated starting from the beginning of
cognitive deficits as reported by patients’ assistants), mini
mental state examination [MMSE; Folstein et al., 1975;
Measso et al., 1993] scores, or education. Eleven healthy
subjects (HS) matched with patients with AD for age and
gender were also enrolled in the study and served as con-
trols. All subjects underwent a neuropsychological assess-
ment to obtain the cognitive profile of patients, and to
exclude any remarkable cognitive impairment in controls,
who were screened using a shorter neuropsychological
battery than the patients. None of the subjects included in
this study took part in our previous study on ACM [Boz-
zali et al., 2011b]. Subjects were excluded if they had either
two or more hyperintense lesions with a diameter 10
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mm or more than eight hyperintense lesions with a diame-
ter between 5 and 10 mm on dual-echo MR images, to
minimize the risk of concomitant vascular pathology [Boz-
zali et al., 2002; Gili et al., 2011; Serra et al., 2010a]. HS
had to show no evidence of cognitive deficits on neuropsy-
chological testing. Major systemic, psychiatric, and other
neurological illnesses were carefully investigated and
excluded in all subjects. Local Ethical Committee approval
and written informed consent (either from the subjects or
from their responsible guardians if incapable) were
obtained before study initiation.
Neuropsychological Assessment
The neuropsychological battery was administered to
patients with AD by two trained neuropsychologists 48 h
before MRI. It included a global cognitive evaluation, using
the MMSE [Folstein et al., 1975; Measso et al., 1993], and
tests specific for each cognitive domain: (1) Verbal episodic
long-term memory: Immediate and Delayed recall of a 15-
Word List [Carlesimo et al., 1996]; Short Story Recall [Carle-
simo et al., 2002]; (2) Visuo-spatial episodic long-term mem-
ory: Delayed recall of Complex Rey’s Figure [Carlesimo
et al., 2002]; (3) Short-term memory: Digit span and Corsi
Block Tapping task [Orsini et al., 1987]; (4) Executive func-
tions and attention: Phonological Word Fluency [Carlesimo
et al., 1996]; (5) Language: Naming subtest of BADA [Miceli
et al., 1991]; (6) Problem-solving: Raven’s Coloured Progres-
sive Matrices [Carlesimo et al., 1996]; (7) Praxis: Copy of
drawings and Copy of drawings with Landmarks [Carle-
simo et al., 1996]; Copy of Complex Rey’s Figure [Carlesimo
et al., 2002]. HS were screened using a shorter neuropsy-
chological battery, including: MMSE; delayed recall of a 15-
Word List; Digit span and Corsi Block Tapping task; Pho-
nological Word Fluency; Raven’s Colored Progressive Mat-
rices; copy of drawings. For each administered test
appropriate adjustments for sex, age and education were
applied according to the Italian normative data (reported in
the references listed next to each test).
MRI Acquisition and Pre-Processing
Subjects were scanned using a head-only 3T MRI system
(Magnetom Allegra Siemens, Erlangen, Germany). The fol-
lowing sequences were acquired in a single session: (1)
dual-echo turbo spin echo (TSE; TR ¼ 6190 ms, TE ¼ 12/
109 ms); (2) fast-fluid-attenuated-inversion-recovery
(FLAIR; TR ¼ 8170 ms, TE ¼ 96 ms); (3) 3D Modified-
Driven-Equilibrium-Fourier-Transform (MDEFT) scan (TR
¼ 1338 ms, TE ¼ 2.4 ms, Matrix ¼ 256  224  176, in-
plane FOV ¼ 250  250 mm2, slice thickness ¼ 1 mm); (4)
Diffusion weighted (DW) twice-refocused [Reese et al.,
2003] spin echo echo-planar imaging (SE EPI; TR ¼ 7 s, TE
¼ 85 ms, b factor ¼ 1000 s/mm2, isotropic resolution ¼ 2.3
mm3), collecting seven images with no diffusion weighting
(b ¼ 0) and 61 images with diffusion gradients applied
along 61 non-collinear directions.
According to the inclusion criteria, TSE and FLAIR scans
were reviewed to exclude the presence of macroscopic brain
abnormalities. Diffusion data were corrected for misalign-
ment between volumes according to the following steps: (i) b
¼ 0 images were realigned to the first volume with a rigid
body transformation computed using the FMRIB’s Linear
Image Registration Tool [FLIRT; Jenkinson and Smith, 2001],
and averaged; (ii) the 61 DW volumes were averaged and
coregistered to the scalp stripped mean b ¼ 0 image, to yield
an average transformation (Tx1) matching the mean DW
image to the mean b ¼ 0; (iii) each DW volume was real-
igned to the mean DW image (with a rigid body transforma-
tion, described by Tx2), and the transformation matching
each DW volume with the b ¼ 0 image was obtained by
combining Tx2 with Tx1. The b matrices were rotated accord-
ingly [Leemans and Jones, 2009]. All the remaining
processing was done using the Camino toolkit (www.
camino.org.uk), if not otherwise specified. The diffusion ten-
sor was estimated in every voxel [Basser et al., 1994], and
maps of fractional anisotropy (FA) were obtained. Each FA
map was used as a reference for affine registration of the
corresponding T1-weighted anatomical image using Statisti-
cal Parametric Mapping 8 (SPM8; Wellcome Department of
Imaging Neuroscience; http://www.fil.ion.ucl.ac.uk/spm/).
Once registered, the anatomical images were segmented into
WM, GM, and cerebrospinal fluid using SPM8. For every
subject a binary parenchymal mask was obtained by adding
GM and WM segments. The resulting image, whose intensity
reflects each voxel’s probability of containing parenchyma,
was thresholded to retain only those voxels with intensity
greater than 0.8, and binarized. As in our preliminary study
[Bozzali et al., 2011b], we used the Q-ball algorithm [Tuch,
2004] to process the DTI data, as it provides a model of dif-
fusion able to resolve more than one direction per voxel.
Tuch’s original radial-basis function formulation [Tuch, 2004]
was employed, as implemented in Camino with the default
parameter settings [Seunarine et al., 2007].
TABLE I. Principal demographic and clinical











Mean (SD) age [years] 72.1 (7.4) 74.7 (7.6) 71.3 (8.4)
Gender (F/M) 10/9 12/7 7/4
Mean (SD) years of education 11.0 (3.9) 9.5 (2.1) 12.4 (3.0)
Mean (SD) MMSE score 18.4 (4.8) 18.3 (4.0) 28.9 (1.6)
*Median (range) disease
duration (months)
31.5 (9–58) 32.0 (10–57) –
*Disease duration was calculated starting from the beginning of
cognitive deficits as reported by patients’ assistants.
AChEIs, Acetylcholinesterase inhibitors; HS, healthy subjects;
MMSE, mini mental state examination; SD, standard deviation.
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Computation of the Anatomical
Connectivity Maps
To generate the anatomical connectivity maps (ACMs),
probabilistic tractography based on the probabilistic index
of connectivity (PICo) method [Parker et al., 2003], was
used. The algorithm accounts for the uncertainty associ-
ated with the determination of the principal directions of
diffusion in every voxel by generating a probability den-
sity function (PDF) of estimated fiber alignment from the
average principal directions derived from Q-ball modelling
of each voxel [Seunarine et al., 2007]. This provides voxel-
wise estimates of the confidence in fiber tract alignment,
which are then used in the probabilistic tract-tracing pro-
cedure. Streamline tracking was then performed, with 10
Monte Carlo iterations from all voxels in the parenchymal
mask.
ACMs were obtained as previously described in detail
[Bozzali et al., 2011b]. Briefly, the total number of stream-
lines passing through each voxel was counted. Then, con-
nectivity maps were divided by the maximum possible
count (sum of the number of voxels tracked, weighted by
the number of diffusion directions per voxel times the
number of Monte Carlo iterations) to normalize for brain
volume. The resultant ACMs were smoothed using an 8
mm3 Gaussian kernel before statistical analysis.
Statistical Analysis
Voxel-wise statistics was carried out using SPM8. Three
separate models were used to assess: (1) the presence of
between-group ACM differences (adjusting for age, gen-
der, education, and number of voxels in the parenchymal
mask); (2) the correlation between regional ACM and the
dosage-x-duration of therapy product (in patients under
AChEIs treatment); (3) the relationship between ACM and
the global level of cognition (as measured by MMSE score)
in patients, classifying them into two separate groups
(drug naı̈ve or under medication, adjusting for age and
number of parenchymal voxels).
For the between-group comparison (1), three groups
were modelled: HS, patients with AD under AChEI, and
patients with AD drug-naı̈ve. T-contrasts were used for
testing specific hypotheses.
For the correlation between regional ACM value and the
dosage-x-duration of therapy (2), only the ACM maps of
the 19 patients under medication were used, and we had
to convert dosages of Donepezil and Rivastigmine into a
TABLE II. Neuropsychological assessment of studied subjects










Verbal episodic long-term memory
15-Words List Immediate recall (cut-off  28.5) 20.4 (10.3)* 24.2 (7.1)# 47.7 (10.3)
Delayed recall (cut-off  4.6) 1.5 (2.0)* 2.6 (2.7)# 9.9 (2.1)
Recognition: hit rates 8.4 (4.2) 7.7 (4.8) –
Recognition: false 7.4 (7.6) 7.1 (7.2) –
Visuo-spatial episodic long-term memory
Complex Rey’s figure Immediate recall (cut-off > 6.4) 5.3 (1.5) 6.0 (5.3) –
Delayed recall (cut-off > 6.3) 3.0 (2.5) 2.9 (4.2) –
Visuo-spatial short-term memory
Digit span (cut-off > 3.7) 4.5 (1.1)* 4.9 (1.3)# 6.0 (1.1)
Corsi Block Tapping task (cut-off  3.5) 3.6 (1.4)* 3.4 (1.6)# 5.22 (0.8)
Executive functions
Phonological Word Fluency (cut-off > 17.3) 20.3 (8.0)* 23.4 (10.5)# 35.9 (8.4)
Language
Naming of objects (cut-off > 22) 24.0 (5.8) 24.3 (5.8) –
Reasoning
Raven’s Coloured Progressive Matrices (cut-off > 18.9) 20.5 (7.1)* 20.4 (6.8)# 34.0 (2.3)
Constructional praxis
Copy of drawings (cut-off > 7.1) 6.8 (3.5)* 7.0 (3.2)# 11.2 (1.0)
Copy of drawings with landmarks (cut-off > 61.8) 54.5 (19.7) 49.5 (19.9) –
Copy of Complex Rey’s Figure (cut-off > 23.7) 13.5 (12.1) 14.8 (9.7) –
For each administered test appropriate adjustments for sex, age and education were applied according to the Italian normative data.
For each test, cut-off scores of normality (95% of the lower tolerance limit of the normal population distribution) are reported in
brackets.
AD, Alzheimer’s disease; AChEIs, acetylcholinesterase inhibitors; HS, healthy subjects.
*P  0.05 AD under AChEIs versus HS.
#P  0.05 Drug-naı̈ve AD versus HS.
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common unit. As the typical therapeutic approach con-
sists, in both cases, of the prescription of a low dosage, fol-
lowed by a progressive increase, up to a maximum dose,
we used the maximum (12 mg for Rivastigmine and 10 for
Donepezil) as the reference for rescaling all dosages.
Therefore, each dosage of Rivastigimane was rescaled as
10/12. Furthermore, the type of drug was modelled as an
additional covariate of no interest. The threshold for statis-
tical significance was set at P < 0.001.
Finally, for the ACM versus MMSE analysis, two groups
were modelled (drug naı̈ve and under medication), and
the group by MMSE interaction was explored.
Post Hoc WM Tract Reconstruction
To interpret the findings of the voxel-wise analysis, we
repeated the ACM computation, this time only accepting
those streamlines that passed through the region we found
to be significantly associated with drug exposure in
patients (see Results). The same parameters used for the
main analysis (same seeding mask, number of iterations ¼
10) were employed. The resulting images were warped
into standard space and averaged across subjects to yield
a representative map of the tract for each group (HS,
patients with AD under AChEIs, and drug-naı̈ve patients).
RESULTS
Subject Characteristics
There were no differences between patients with AD
and HS with respect to age, gender, and education (Table
I). As expected, all patients with AD showed a widespread
cognitive impairment, with no significant differences
between subgroups (those drug-naı̈ve and those under
AChEI medication; Table II).
ACM
Between group comparisons
When comparing all patients with AD with HS, ACM
values were found to be reduced (P < 0.001) in AD in the
fornix, in the supramarginal gyrus (bilaterally) and in the
cingulum (Fig. 1A), whereas they were increased along the
cortico-spinal tracts (Fig. 1B). When contrasting either sub-
group of patients with AD (those drug-naı̈ve and those
under AChEI medication) against HS separately, ACM
was found to be significantly altered in the same areas as
when considering all patients as a single group (data not
shown).
An additional comparison was carried out by contrast-
ing only the patients with AD (N ¼ 7) who were treated
with the maximum dose of AChEIs (either 10 mg daily for
Donepezil or 12 mg daily for Rivastigmine) with HS, high-
lighting a region of increased ACM values in the right
hemisphere, centred at MNI coordinates: (28, 13, and 16),
comprising the putamen and the anterior limb of the inter-
nal capsule (Fig. 2A). The location of this area is consistent
with previously reported findings [Bozzali et al., 2011b].
Correlation analyses
When analyzing the correlation between ACM and dose
 duration of therapy, a strong positive association was
observed in the right anterior limb of the internal capsule
(Fig. 2B). When looking at the relationship between MMSE
and ACM, a significant (P < 0.001) MMSE score  group
(drug naive vs. under therapy patients) interaction was
observed in the same area (Fig. 3), indicating that drug-
free patients show a direct correlation between their
MMSE scores and ACM values in that area, which is lost
in patients under AChEIs.
Figure 1.
Voxel-wise comparison of ACM values between patients with
AD and HS. Reductions of structural connectivity in patients are
shown in red (panel A), whereas increases are shown in blue
(panel B). The reductions located in the fornix, in the supramar-
ginal gyri and in the cingulum are consistent with a progressive
disconnection between the medial temporal lobes and the rest
of the brain. The increased ACM values in the cortico-spinal
tract might reflect a relative sparing of this WM tract compared
to association bundles (i.e., the superior longitudinal fasciculus).
See text for further details.
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Post hoc ‘‘selective’’ ACM reconstruction
The ACM reconstruction obtained only retaining the
connections passing through the region of positive correla-
tion observed between ACM values and dose  duration
product of AChEIs (Fig. 2B) was consistent across subjects.
The group-averaged images of these maps (Fig. 2C), indi-
cate that the main WM tract crossing that region is the
right anterior thalamic radiation.
DISCUSSION
In this study, we recruited a cohort of patients with
probable AD, with equal numbers under AChEIs and
drug-naı̈ve. The former subgroup included patients who
had been under treatment for a variable time, ranging
from 6 months up to 2 years. The shortest treatment dura-
tion was chosen to ensure an exposure time that could be
compatible with putative processes of brain plasticity. The
longest duration was chosen to avoid a significant gap in
clinical staging between treated and untreated patients.
Within-subject variability in treatment exposure (dose and
duration) was welcomed to allow a correlation analysis
with imaging data.
Figure 2.
Panel A: Region of increased ACM values (light blue area) in
patients with AD treated with the maximum dose of AChEIs
compared to healthy controls; this area includes the putamen
and the anterior limb (non motor portion) of the right internal
capsule. Panel B: Direct associations (red areas) between ACM
values and dosage-x-duration of therapy product in the group of
patients under treatment with Acetylcholinesterase inhibitors
(AChEIs). The area of significant association is located again
within the anterior limb of the internal capsule. This area is
proximal to the cholinergic basal forebrain, supporting a putative
neurotrophic and neurorestorative role of AChEIs. Panel C:
‘‘Selective’’ ACM maps (area shown in red in panel B) obtained
when using the area shown in panel B as way-point (i.e., retain-
ing only streamlines passing through it). The figure shows the av-
erage maps for healthy controls and Alzheimer’s disease (AD)
patients. The main tract coincides with the known anatomical
pathway of the anterior thalamic radiation. Spatial coordinates in
the figure are in MNI space. See text for further details.
Figure 3.
Effect of the interaction between the administration of Acetyl-
cholinesterase inhibitors (AChEIs; yes or no) and the global level
of cognition [as measured by mini mental state examination
(MMSE) score] on anatomical connectivity (ACM) of patients
with AD. This area (shown in red) largely overlaps with the one
found to be directly associated with exposure to AChEIs, as
shown in Figure 2 (panel B). The design matrix used to test the
interaction is reported on the left. It includes the two groups of
patients modelled separately (those under treatment and those
drug-naı̈ve), their correspondent MMSE scores (covariate of in-
terest), and their age and brain volumes (covariates of no inter-
est). In the graph, there is reported association between
individual MMSE scores and ACM values derived from the brain
area of interaction for the two groups of patients, those drug-
naı̈ve (violet) and those under medication (blue). This direct cor-
relation, which is present in the former group of patients, is lost
in the latter one. See text for further details.
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When contrasting all patients with AD against HS, ACM
values were reduced in the supramarginal gyri, in the
cingulum, and in the fornix of the former group. This ana-
tomical distribution confirms and extends our exploratory
findings [Bozzali et al., 2011b], and supports, on a ‘‘struc-
tural’’ basis, the critical role of brain disconnection in AD
pathophysiology [Gili et al., 2011; Villain et al., 2005].
Reduced ACM values in the supramarginal gyrus and
cingulum of patients with AD represents a robust finding,
which is highly consistent with previous literature [Gili
et al., 2011; Greicius et al., 2004; Ibáñez et al., 1998; Nestor
et al., 2003]. It has been demonstrated that functional dis-
connection of the posterior cingulate cortex in AD, pre-
cedes the occurrence of GM atrophy in the same area [Gili
et al., 2011], and different combinations of structural dam-
age to the cingulum and GM loss around it, respond to
different clinical stages [Bozzali et al., 2011]. On the other
hand, the fornix was previously reported to be critical for
the conversion from MCI to AD [Copenhaver et al., 2006].
ACM was increased in the corticospinal tracts of
patients with AD. Because of the normalisation of ACM
maps by the total number of streamlines initiated, the
overall reduction in connectivity may translate into an arti-
ficial increase of connectivity of those tracts (i.e., cortico-
spinal tracts) which are relatively spared by AD pathology
[Bozzali et al., 2002]. An alternative explanation is pro-
vided with reference to a recent study by another group
[Douaud et al., 2011], investigating the ‘‘mode of anisot-
ropy,’’ an index reflecting how ‘‘linear’’ (as opposed to
‘‘planar’’) the shape of diffusion tensor is in a voxel. This
study revealed, unexpectedly, an increase of this index in
patients with AD, located in the area where the corticospi-
nal tract crosses the superior longitudinal fasciculus. The
Authors concluded that this paradoxical result is due to a
selective sparing of the corticospinal tracts. In the current
study, it is likely that the tractography algorithm used for
ACM, encountered less alternative, confounding, pathways
from the corticospinal tract through the superior longitudi-
nal fasciculus or corpus callosum in patients with AD than
in controls, thus generating an artificial increase of ACM
values confined to the corticospinal tracts. Similar
‘‘unmasking’’ effects have previously been reported in
apparently paradoxical increases in FA observed in normal
appearing deep gray matter in multiple sclerosis [Ciccarelli
et al., 2001].
When contrasting the two AD subgroups (patients
under treatment and patients drug-naı̈ve) in isolation
against HS, patterns of reduced ACM values were similar
to those observed in the whole AD population. Moreover,
no significant difference was observed in the ACM
between the two subgroups of patients. This suggests that
reduced brain connectivity in the cingulum, in the supra-
marginal gyri and in the fornix may be responsible for
patients’ cognitive disabilities, independently of AChEI
medication. This aspect does not necessarily mean that
AChEIs are ineffective in modulating AD pathophysiol-
ogy. The two groups of patients were indeed matched for
cognitive decline and disease duration. Interestingly, when
limiting the analysis to those patients under maximum
dosage of AChEIs, we were able to replicate our previous
findings of increased ACM [Bozzali et al., 2011b]. Consis-
tently, the most striking result of the current study is the
positive impact of AChEIs (dosage-x-time) on AD brains.
Such an effect was found in a region between the putamen
and the caudate, identified by tractography as belonging
to the right anterior thalamic radiation. The anterior tha-
lamic radiation connects the thalamus to the prefrontal
cortex, does not carry motor pathways, and is relevant for
higher level functions. Interestingly, the correlation analy-
sis performed here, which intrinsically accounts for differ-
ent treatment dosages and durations, returned a similar
anatomical localisation for the changes in ACM values pre-
viously observed in a independent group of patients [Boz-
zali et al., 2011b]. We speculate that this drug related
effect may reflect a putative neurotrophic and neurorestor-
ative role that AChEIs have been reported to exert on cho-
linergic neurons [Ginestet et al., 2007], as suggested by
long-term stabilizing effects of AChEIs in AD [Giacobini,
2002]. Although preliminary, this interpretation is also
supported by the positive effect that, according to our
results, medication plays in modulating the relationship
between MMSE scores and structural connectivity, again,
along the anterior thalamic radiation. This area of drug
modulation (obtained in a data-driven fashion) is particu-
larly intriguing for its proximity to the cholinergic basal
forebrain, as shown by others [Grothe et al., 2010; Hanyu
et al., 2002]. The cholinergic modulation found in the ante-
rior thalamic radiation is interesting also for the connec-
tion of this structure to the medial-dorsal nucleus of the
thalamus [Wakana et al., 2004], which, in turn, is known
to project to brain areas implicated in the control of behav-
ior [e.g., the anterior cingulate and the dorsolateral pre-
frontal cortex; Eckert et al., 2011]. In recent years, great
interest has been dedicated to clarify the neurobiological
substrate underling the neuropsychiatric and behavioral
aspects (also known as behavioural and psychological
symptoms of dementia [BPSD], see IPA 1996) of AD
[Bruen et al., 2008; Rosen et al., 2004; Serra et al., 2010].
The pathophysiology of BPSD in AD has not been clearly
delineated yet. However, a direct association between the
occurrence and severity of dysinhibition and neurodegen-
eration of the anterior cingulate cortex was recently
reported [Serra et al., 2010b]. Although future studies are
needed to assess whether a direct association exists
between changes in anterior thalamic radiation and BPSD,
we speculate that the modulation of ACM we observed
here might be related to a potential interaction between
AChEIs and BPSD. A clinical effect of AChEIs on BPSD in
patients with AD has been recently suggested by Lockhart
and coworkers [2011]. Moreover, consistent with the spe-
cific effect of interaction we found between AChEIs
administration (yes/no) and the MMSE score on patients
ACM in the anterior thalamic radiation, other Authors
have suggested that these reduced neuropsychiatric
r Bozzali et al. r
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symptoms in AD may help to improve the results detecta-
ble on global cognitive measures [Brousseau et al., 2007].
In this perspective, our findings might reflect, on a neuro-
biological basis, a potential explanation for the some clini-
cal effects of AChEI therapy.
With respect to a more specific interpretation of ACM
changes in terms of the neurobiological substrate, we
hypothesize that an increased number of regenerating
axons and sprouting of collateral fibers might explain the
observed modulation in the brain of patients under
AChEIs. This finding seems relatively robust as the same
area of ACM modulation came out from two independent
analyses involving patients with AD under medication
[see Bozzali et al., 2011b]. In support to this hypothesis,
which remains speculative, it has been proposed that the
cholinergic stimulation of oligodendrocytes might play a
critical role in promoting brain myelination during brain
development, and might also contribute to mechanisms of
myelin repair in older age [Bartzokis et al., 2007].
In a recent study, Likitjaroen and coworkers investi-
gated, in a longitudinal placebo-controlled study of
patients with AD, the potential effect of Galantamine in
preserving the regional FA in a set of selected WM regions
(i.e., the corpus callosum, the cingulum, and the cerebel-
lum), and reported only a limited impact of the treatment
[Likitjaroen et al., 2011]. This is only apparently inconsis-
tent with our findings for several reasons. First, the ante-
rior thalamic radiation was not included in the set of
regions investigated by Likitjaroen et al., thus making a
direct comparison between the two studies difficult. More-
over, in contrast to ACM, FA expresses only an index of
regional WM integrity, and does not provide any informa-
tion on the structural brain connectivity. Finally, if our
interpretation of sprouting of collateral fibers is correct,
this phenomenon is expected to reduce rather than
increase the FA locally. This might have mitigated the
expected effect of Galantamine (FA preservation) in the
study conducted by Likitjaroen et al. [Likitjaroen et al.,
2011].
One limitation of this study is the inclusion of patients
being treated with either Donepezil or Rivastigmine, the
former inhibiting the acetylcholinesterase enzyme only, the
latter inhibiting both the cholinesterase and the butyryl-
cholinesterase enzymes. Because of the partially different
pharmacodynamics of Donepezil and Rivastigmine, there
are no available conversion tools to make the two drug
doses interchangeable. On the other hand, the common
effect of both drugs is to increase the availability of acetyl-
choline in neuronal synapses, and adjusted indirect com-
parisons found drugs to be similar, at least with respect to
their cognitive outcomes [Hansen et al., 2008; Ritchie et al.,
2004]. Additionally, within the obvious oversimplification
of including patients under both Donepezil or Rivastig-
mine, the type of drug were modelled as a covariate of no
interest in our analyses. Nevertheless, a differential investi-
gation of Donepezil and Rivastigmine is of great interest
and needs to be addressed by future studies. Another limi-
tation of the current study is the small sample size. This is
particularly evident when attempting to replicate previous
findings [Bozzali et al., 2011b] through a between-group
comparison of patients under AChEIs and patients drug
naı̈ve, which reached statistical significance only when
including those patients assuming AChEIs at the highest
doses (n ¼ 7). However, as already mentioned, the area of
ACM modulation found in this between group contrast
was similar to that found in both a previous independent
study [Bozzali et al., 2011b] and in an independent statisti-
cal analysis of correlation (dosage-x-duration of therapy
product), which included patients under medication only.
Nevertheless, these findings need to be confirmed in
future studies on larger populations.
Finally, as ACM is based on probabilistic tractography,
it is important to reiterate that it suffers from all the well-
known limitations of the technique. In particular, tractog-
raphy is sensitive only to the larger pathways of the brain
and, even when probabilistic methods are combined with
multi-fibre decomposition methods, as used here, the
results of tractography can be confounded by fibre cross-
ings, kissings, and divergence.
In conclusion, this study further demonstrates how
brain disconnection is relevant for the understanding of
AD pathophysiology. Moreover, it demonstrates in vivo
the effect of AChEIs in determining brain plasticity and
proposes a new method for monitoring clinical trials in
AD.
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